Myasthenia Gravis Market: By Treatment, By End User and Geography

Myasthenia Gravis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Surgery, Medication, and Others), By End User (Hospitals, Clinics, and Others) and Region

Myasthenia Gravis Market is expected to be valued at US$ 1,824.6 million in 2023 and is poised to grow at a CAGR of 8.1% from 2024 to 2030. Myasthenia gravis is an autoimmune disease diagnosis, which means the immune system, which normally protects the body from foreign organisms, misguidedly attacks itself. MG which is an antibody-mediated autoimmune disease is a rare neurological disease. Myasthenia gravis is caused by a failure in the spread of nerve impulses to muscles. As per the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia Gravis (MG) varied from 150 to 200 cases per million. In earlier years, the prevalence of MG was estimated to be 1 in 20,000, which then rose to 1 in 17,000 after the finding of AChR antibodies in 1969. Nevertheless, the mortality rate of the disease is still in the range of 5 and 9 percent and is a bit greater in men than in women. A strong emphasis on introducing new therapies and improving healthcare infrastructure is expanding the myasthenia gravis market growth.

Myasthenia Gravis Market Key Developments:

In May 2022, UK Early Access was Granted for Argenx's generalized myasthenia gravis treatment.

Download Free Sample

Myasthenia Gravis Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.1%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Myasthenia Gravis Market Dynamics

The market for Myasthenia Gravis is primarily driven by the rising incidence of neuromuscular disorders, and the increasing prevalence of the myasthenia gravis, with the geriatric population (65 and older) suffering the biggest incidence of myasthenia gravis. Additionally, the increasing number of clinical trials for effective treatment is another key driver for the growth of the global myasthenia gravis. Furthermore, medical development can be attributed the boosting the growth of the market. Additionally, consistent research and development activities, growing investment by various private players, and progress of technologically advanced drugs are other factors that push the market growth. However, side effects of drugs used in the treatment of myasthenia gravis and the high cost of tools and technologies are expected to restrain the global market growth.

North-America Got Significant Share

Myasthenia Gravis Market Regional Analysis

The North America market is anticipated to grow a significant revenue share in the global Myasthenia Gravis market over the forecast period due to the maximum rising of myasthenia disease in this region all over the world. Furthermore, better facilities are present in the clinical setups in this region, and continuous development in the healthcare infrastructure also propels market growth. On the other hand, the Asia Pacific region is witnessed to grow with the largest revenue share over the forecast period in the Myasthenia market owing to the increasing population day by day consequently rising neuromuscular disorders among a large part of the population.

Latin America

Europe

Asia Pacific

Middle East

North America

Myasthenia Gravis Market Segmentation Analysis

Report Benchmarks	Details
Report Study Period	2024-2030
Market Size in 2023	US$ 1,824.6 million
Market CAGR	8.1%
By Treatment	Surgery Medication Others
By End User	Hospitals Clinics Others
By Region	North America Europe The Asia Pacific Latin America MEA

Key Features of the Report

The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
The report tracks recent innovations, key developments, and start-up details that are actively working in the market
The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Myasthenia gravis is an autoimmune disease, which means the immune system, which normally protects the body from foreign organisms, misguidedly attacks itself. MG which is an antibody-mediated autoimmune disease is a rare neurological disease

Growing incidence of neuromuscular disorders, and the increasing incidence of the myasthenia gravis, with the geriatric population (65 and older) suffering the biggest incidence of myasthenia gravis

Medications can dramatically inhibit the immune system and mostly accomplish the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), immunosuppressive drugs, prograf (tacrolimus) corticosteroids, and neoral/Sandimmune (cyclosporine).

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary

2. Global Myasthenia Gravis Market Introduction

2.1. Global Myasthenia Gravis Market Taxonomy

2.2. Global Myasthenia Gravis Market Definitions

2.2.1. Treatment

2.2.2. End User

2.2.3. Geography

3. Global Myasthenia Gravis Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Myasthenia Gravis Market Dynamic Factors - Impact Analysis

3.6. Global Myasthenia Gravis Market Competition Landscape

4. Global Myasthenia Gravis Market Analysis 2019 - 2023 and Forecast, 2024 - 2030

4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. Global Myasthenia Gravis Market, By Treatment, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1. Surgery

5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Medication

5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Others

5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

6. Global Myasthenia Gravis Market Forecast, By End User,2019 - 2023and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1. Hospitals

6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Clinics

6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Others

6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

7. Global Myasthenia Gravis Market Forecast, By Region, 2019 - 2023and Forecast, 2024 - 2030(Revenue, USD Mn)

7.1. North America

7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Europe

7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Asia-Pacific

7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Latin America

7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Middle East and Africa

7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User, and Region, 2024 - 2030

8. North America Myasthenia Gravis Market Analysis,2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn)

8.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.1.1. Surgery

8.1.2. Medication

8.1.3. Others

8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.2.1. Hospitals

8.2.2. Clinics

8.2.3. Others

8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.3.1. USA

8.3.2. Canada

8.4. North America Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User, and Country, 2024 - 2030

8.5. North America Myasthenia Gravis Market Dynamics Trends

9. Europe Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn)

9.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Surgery

9.1.2. Medication

9.1.3. Others

9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Hospitals

9.2.2. Clinics

9.2.3. Others

9.3. Country Analysis 2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.3.1. Germany

9.3.2. UK

9.3.3. France

9.3.4. Spain

9.3.5. Italy

9.3.6. Russia

9.3.7. Poland

9.3.8. Rest of Europe

9.4. Europe Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End user and Country, 2024 - 2030

9.5. Europe Myasthenia GravisÂ Market Dynamics Trends

10. Asia-Pacific Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

10.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Surgery

10.1.2. Medication

10.1.3. Others

10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Hospitals

10.2.2. Clinics

10.2.3. Others

10.3. Country Analysis2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.3.1. Japan

10.3.2. China

10.3.3. India

10.3.4. ASEAN

10.3.5. Australia & New Zealand

10.3.6. Rest of Asia-Pacific

10.4. Asia-Pacific Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country,2024 - 2030

10.5. Asia-Pacific Myasthenia Gravis Market Dynamics Trends

11. Latin America Myasthenia Gravis Market Analysis,2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn)

11.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Surgery

11.1.2. Medication

11.1.3. Others

11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Hospitals

11.2.2. Clinics

11.2.3. Others

11.3. Country Analysis 2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.3.1. Brazil

11.3.2. Mexico

11.3.3. Argentina

11.3.4. Rest of Latin America

11.4. Latin America Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country, 2024 - 2030

11.5. Latin America Myasthenia Gravis Market Dynamics Trends

12. Middle East and Africa Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

12.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Surgery

12.1.2. Medication

12.1.3. Others

12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Hospitals

12.2.2. Clinics

12.2.3. Others

12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.3.1. Gulf Cooperation Council (GCC) Countries

12.3.2. Israel

12.3.3. South Africa

12.3.4. Rest of MEA

12.4. MEA Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country, 2024 - 2030

12.5. MEA Myasthenia GravisÂ Market Dynamics Trends

13. Competition Landscape

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Product Type& Service Testing Types, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Alexion Pharmaceutical Inc. (U.S.)

13.2.2. Bausch Health Companies Inc. (Canada)

13.2.3. Grifols SA (Spain)

13.2.4. Avadel Pharmaceuticals plc. (France)

13.2.5. GlaxoSmithKline plc (U.K.)

13.2.6. Novartis AG (Switzerland)

13.2.7. Pfizer Inc. (U.S.)

13.2.8. AbbVie Inc. (U.S.)

13.2.9. F. Hoffmann-La Roche Ltd. (Switzerland)

13.2.10. GlaxoSmithKline plc (U.K.)

13.2.11. Shire plc (U.S.)

14. Research Methodology

15. Key Assumptions and Acronyms

Key Market Players

Alexion Pharmaceutical Inc. (U.S.)
Bausch Health Companies Inc. (Canada)
Grifols SA (Spain)
Avadel Pharmaceuticals plc. (France)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Pfizer Inc. (U.S.)
AbbVie Inc. (U.S.)
Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline plc (U.K.)
Shire plc (U.S.)

Related Industry Reports

Egypt Diabetes Devices Market

Lithuania Surgical Equipment Market

Antimicrobials Market

Cancer Therapy Market